Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

New Procedures Recommended for Improvement of Surgical Blood Transfusion

October 1, 1997
Publication
Article
OncologyONCOLOGY Vol 11 No 10
Volume 11
Issue 10

Clinical data supporting the use of leukocyte-reduced blood indicates a significant decrease in the risk of infection and cost of recovery in surgical patients, according to a panel of experts.

Clinical data supporting the use of leukocyte-reduced blood indicates a significant decrease in the risk of infection and cost of recovery in surgical patients, according to a panel of experts.

The millions of Americans who undergo surgery each year would benefit significantly from the use of leukocyte-reduced blood in transfusion, according to speakers at the recent American Society of Colon and Rectal Surgeons (ASCRS) meeting in Philadelphia. Currently reserved for transfusion in the highest-risk surgeries or cancer patients, leukocyte-reduced blood can significantly decrease the risk of infection, improve clinical outcomes, and decrease recovery time, as well as associated hospital costs with most surgical procedures.

“For surgical patients, transfusion-induced immunosuppression, which increases the risk of postoperative infection, is the single greatest mortality risk from transfusion,” said Neil Blumberg, MD, Strong Memorial Hospital, Rochester, New York. “Procedures that can minimize the risk of these infections, such as the routine use of leukocyte-reduced blood, should become a standard practice for all surgical patients requiring blood transfusions.” He added that the use of leukocyte-reduced blood for surgical patients would represent a potential annual savings of $6,000,000 to $12,000,000 for the US health-care system.

Leukocytes: Culprits of Infection

Blood transfusion has been linked with an increased occurrence of postoperative infections, such as pneumonia, wound infection, and sepsis. This increased risk has been shown in every surgical situation studied, including burn, cardiovascular, colorectal, hip, spinal, and trauma surgery.

“Since most people undergoing surgery are already sick, any measure that can eliminate the risk of additional infections, which can be life-threatening, should be adopted now,” said Richard Spence, MD, Staten Island University Hospital, New York. “Removing leukocytes from donor blood can be easily achieved through the use of blood filters either at the patient’s bedside or in the blood bank.”

Clinical Studies Indicate Reductions in Infection, Hospital Stay, and Costs

Lone Jensen, MD, Aarhus Municipal Hospital, Denmark, discussed the results of a study of 589 colorectal surgery patients that compared infection rates of leukocyte-reduced blood transfusions with allogeneic blood transfusions. She reported that when leukocyte-reduced blood was transfused, infection rates for pneumonia dropped from 23% to 3%. This rate of infection was identical to that seen in patients who received no transfusions. This study also showed that patients who received unfiltered blood had a significantly higher frequency of wound infection (12%) and rate of reoperation (16.9%) compared with patients who were transfused with leukocyte-reduced blood (0% and 3.5%).

A separate study of 915 cardiac surgery patients by van de Watering and coworkers found that leukocyte-reduced blood transfusions resulted in a noteworthy reduction in postoperative mortality by lowering the noncardiac causes of death in the study group. Noncardiac postoperative mortality was 7.6% with allogeneic blood compared with 2.5% with leukocyte-reduced blood by filtration.

“Allogeneic blood transfusion not only correlates with high infection rates but has also been significantly related to an increased length of hospital stay that is required to treat the infection,” stated Paul Tartter, MD, Mount Sinai Medical Center, New York. “Studies have shown a 15% to 35% reduction in hospital stay in surgical patients transfused with leukocyte-reduced blood. This translates into a significant reduction in the costs of hospital care.” Dr. Blumberg noted that the clinical data conclusively show that the use of leukocyte-reduced transfusions considerably decreases the risk of postoperative infections.

Articles in this issue

Vinorelbine in Non-Small-Cell Lung Cancer
Paclitaxel and Vinorelbine in Non-Small-Cell Lung Cancer
Safety Data From North American Trials of Vinorelbine
Cisplatin Alone vs Cisplatin Plus Vinorelbine in Stage IV NSCLC
Doublets and Triplets: New Drug Combinations in the Palliative Care of NSCLC
Current Management of Unresectable Non-Small-Cell Lung Cancer
Concomitant Cisplatin, Vinorelbine, and Radiation in Advanced Chest Malignancies
Vinorelbine and Carboplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer
Historical Review of Trials With Vinorelbine in Non-Small-Cell Lung Cancer
The Economics of Prostate Cancer Screening
Single-Agent Pegylated Liposomal Doxorubicin in Cancer: Current Status and Future Applications
Coalition President Urges Policy Board to Focus on the Policy and Practices Affecting Cancer Research
Researchers Studying Effects of Green Tea on Cancer Patients
New Procedures Recommended for Improvement of Surgical Blood Transfusion
Possible New Approach to Brain Tumors in AIDS Patients
Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Related Content
Advertisement

A subgroup analysis of OS showed that results were favorable with amivantamab plus lazertinib in patients who are Asian.

Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population

Tim Cortese
September 12th 2025
Article

Full overall survival results with amivantamab plus lazertinib from the Asia cohort of the MARIPOSA trial will be shared at a future medical conference.


At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.

Optimizing Care Planning for Variant Histology Populations at World GU 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Bradley G. Somer, MD
September 11th 2025
Podcast

At World GU 2025, experts discussed forming treatment strategies for patients with variant histologies across prostate, bladder, and kidney cancer.


No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.

SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC

Roman Fabbricatore
September 11th 2025
Article

No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.


Upfront risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.

Cardiovascular Considerations in Breast Cancer Treatment and Survivorship

Joseph S. Wallins, MD, MPH
September 8th 2025
Podcast

Up-front risk stratification for additional cardiovascular testing may help mitigate cardiovascular toxicities in breast cancer treatment.


In all 9 patients treated with vobramitamab duocarmazine, no objective responses were reported.

Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC

Tim Cortese
September 11th 2025
Article

After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.


The complete response (CR) rate was 51.4% with M-Pola vs 24.3% with R-GemOx, respectively.

What Makes M-Pola Superior to R-GemOx in Transplant-Ineligible LBCL?

Tim Cortese
September 11th 2025
Article

Results from the SUNMO trial showed that mosunetuzumab plus polatuzumab vedotin achieved a complete response rate of 51.4% in this LBCL population.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.